HER2阳性乳腺癌中CD44v6的表达与曲妥珠单抗耐药的关系

目的：探讨曲妥珠单抗在治疗HER2阳性的转移性乳腺癌时,产生耐药性与CD44v6表达的相关性。方法：共66例HER2阳性转移性乳腺癌患者入组。接受曲妥珠单抗治疗的患者37例,其中18例获得了治疗前和治疗后转移性癌组织。采用免疫组化S-P法对治疗前、治疗后的不同乳腺组织进行CD44v6表达的研究。结果：CD44v6在经曲妥珠单抗治疗产生耐药的活检组织中阳性表达程度明显高于治疗前。结论：CD44v6的表达与曲妥珠单抗耐药相关。

Relationship between Expression of CD44v6 and Resistance of Trastuzumab Chemotheraphy in Metastatic Breast Cancer Patients with HER2 Positive

Objective：To explore the correlation between the expression of CD44v6 and resistance of trastuzumab chemotheraphy for metastatic breast cancer patient with HER2 positive.Methods：66 metastatic breast cancer patients with HER2 positive were eligible.Among 66 patients,37 were received trastuzumab,and there were 18 patients who had tumor tissues before and after therapy.All species were analyzed by S-P immunohistochemical method using the monoclonal antibody CD44 v6.Results：CD44v6 in breast cancer tissues of resistance to traszuzumab were signifcantly higher than before the treatment.Conclusion：There may be correlation between the expression of CD44v6 and resistance to trastuzumab.